


SUPPLEMENTARY FIGURES




Supplementary Figure 1. Association of *NLRP3* mutations with TMB in 2 ICGC melanoma cohorts. *NLRP3* mutations versus TMB with (A) univariate analysis and (B) multivariate regression model in MELA-AU cohort; *NLRP3* mutations versus TMB with (C) univariate analysis and (D) multivariate regression model in SKCA-BR cohort.



Supplementary Figure 2. Infiltration of overall immune cells in patients with and without NLRP3 mutations.




Supplementary Figure 3. Infiltration of 31 immune cells stratified by *NLRP3* mutation status according to Angelova et al. method.




Supplementary Figure 4. Expression of 33 immune checkpoint genes stratified by *NLRP3* mutation status.

Mutated NLRP3 pathways Gene ranks NES P FI ARACHIDONIC_ACID_METABOLISM
HEDGEHOG_SIGNALING_PATHWAY MMIN
BASAL_CELL_CARCINOMA I III - WILHILL III IIII 1.95 7.1e-04 5.76
COMPLEMENT_AND_COAGULATION_CASCADES
LINOLEIC_ACID_METABOLISM IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
GRAFT_VERSUS_HOST_DISEASE 110 11 11 2.02 1.1e-03 7.1e
ECM_RECEPTOR_INTERACTION
CELL_ADHESION_MOLECULES_CAMS
ALLOGRAFT_REJECTION 1.74 5.4e-03 2.4e
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION


Supplementary Figure 5. GSEA analysis of *NLRP3* mutant patients.




Supplementary Figure 6. Clinical characteristics association with ICI efficacy. Association of (A) TMB, (B) age, (C) gender, (D) stage, and (E) treatment type with ICI response rate and prognosis.



Supplementary Figure 7. Correlation of *NLRP3* mutations with TMB in the pooled ICI-treated cohort. (A) Wilcoxon rank-sum test and (B) multivariate Logistic regression analysis for the correlation of *NLRP3* mutations with TMB.



Supplementary Figure 8. Kaplan-Meier survival analysis of *NLRP3* mutations in 3 non-ICI-treated cohorts.



Supplementary Figure 9. *NLRP3* and *IL-1* β mRNA expression concerning *NLRP3* mutational status in melanoma based on the data from TCGA cohort. (A) Correlation analysis between *NLRP3* and *IL-1* β expression. Distinct expression of (B) *NLRP3* and (C) *IL-1* β in *NLRP3* wild-type versus mutated subgroups.